Tags

Type your tag names separated by a space and hit enter

Kava-kava extract WS 1490 versus placebo in anxiety disorders--a randomized placebo-controlled 25-week outpatient trial.
Pharmacopsychiatry 1997; 30(1):1-5P

Abstract

101 outpatients suffering from anxiety of non-psychotic origin (DSM-III-R criteria: agoraphobia, specific phobia, generalized anxiety disorder, and adjustment disorder with anxiety) were included in a 25-week multicenter randomized placebo-controlled double-blind trial with WS 1490, a special extract of kava-kava. In the main outcome criterion, the Hamilton Anxiety Scale (HAMA), there was a significant superiority of the test drug starting from week 8 on. WS 1490 was also found to be superior with respect to the secondary outcome variables. HAMA subscores somatic and psychic anxiety, Clinical Global Impression, Self-Report Symptom Inventory-90 Items revised, and Adjective Mood Scale. Adverse events were rare and distributed evenly in both groups. These results support WS 1490 as a treatment alternative to tricyclic antidepressants and benzodiazepines in anxiety disorders, with proven long-term efficacy and none of the tolerance problems associated with tricyclics and benzodiazepines.

Authors+Show Affiliations

Department of Psychiatry, Jena University, Germany.No affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Multicenter Study
Randomized Controlled Trial

Language

eng

PubMed ID

9065962

Citation

Volz, H P., and M Kieser. "Kava-kava Extract WS 1490 Versus Placebo in Anxiety Disorders--a Randomized Placebo-controlled 25-week Outpatient Trial." Pharmacopsychiatry, vol. 30, no. 1, 1997, pp. 1-5.
Volz HP, Kieser M. Kava-kava extract WS 1490 versus placebo in anxiety disorders--a randomized placebo-controlled 25-week outpatient trial. Pharmacopsychiatry. 1997;30(1):1-5.
Volz, H. P., & Kieser, M. (1997). Kava-kava extract WS 1490 versus placebo in anxiety disorders--a randomized placebo-controlled 25-week outpatient trial. Pharmacopsychiatry, 30(1), pp. 1-5.
Volz HP, Kieser M. Kava-kava Extract WS 1490 Versus Placebo in Anxiety Disorders--a Randomized Placebo-controlled 25-week Outpatient Trial. Pharmacopsychiatry. 1997;30(1):1-5. PubMed PMID: 9065962.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Kava-kava extract WS 1490 versus placebo in anxiety disorders--a randomized placebo-controlled 25-week outpatient trial. AU - Volz,H P, AU - Kieser,M, PY - 1997/1/1/pubmed PY - 1997/1/1/medline PY - 1997/1/1/entrez SP - 1 EP - 5 JF - Pharmacopsychiatry JO - Pharmacopsychiatry VL - 30 IS - 1 N2 - 101 outpatients suffering from anxiety of non-psychotic origin (DSM-III-R criteria: agoraphobia, specific phobia, generalized anxiety disorder, and adjustment disorder with anxiety) were included in a 25-week multicenter randomized placebo-controlled double-blind trial with WS 1490, a special extract of kava-kava. In the main outcome criterion, the Hamilton Anxiety Scale (HAMA), there was a significant superiority of the test drug starting from week 8 on. WS 1490 was also found to be superior with respect to the secondary outcome variables. HAMA subscores somatic and psychic anxiety, Clinical Global Impression, Self-Report Symptom Inventory-90 Items revised, and Adjective Mood Scale. Adverse events were rare and distributed evenly in both groups. These results support WS 1490 as a treatment alternative to tricyclic antidepressants and benzodiazepines in anxiety disorders, with proven long-term efficacy and none of the tolerance problems associated with tricyclics and benzodiazepines. SN - 0176-3679 UR - https://www.unboundmedicine.com/medline/citation/9065962/Kava_kava_extract_WS_1490_versus_placebo_in_anxiety_disorders__a_randomized_placebo_controlled_25_week_outpatient_trial_ L2 - http://www.thieme-connect.com/DOI/DOI?10.1055/s-2007-979474 DB - PRIME DP - Unbound Medicine ER -